Androgen Deficiency: Association With Increased Anxiety and Depression Symptom Severity in Anorexia Nervosa

2007 ◽  
Vol 68 (06) ◽  
pp. 959-965 ◽  
Author(s):  
Karen K. Miller ◽  
Tamara L. Wexler ◽  
Alicia M. Zha ◽  
Elizabeth A. Lawson ◽  
Erinne M. Meenaghan ◽  
...  
Keyword(s):  
Anorexia Nervosa ◽  
Symptom Severity ◽  
Anxiety And Depression ◽  
Depression Symptom ◽  
Androgen Deficiency

scholarly journals The characteristics of anxiety and depression symptom severity in older adults living in public housing

2011 ◽  
Vol 24 (4) ◽  
pp. 614-623 ◽  
Author(s):  
Adam Simning ◽  
Yeates Conwell ◽  
Susan G. Fisher ◽  
Thomas M. Richardson ◽  
Edwin van Wijngaarden
Keyword(s):  
Public Housing ◽  
Older Adult ◽  
Symptom Severity ◽  
Regression Models ◽  
Late Life ◽  
Anxiety And Depression ◽  
Depression Symptoms ◽  
Depression Symptom ◽  
The Social ◽  
Public Housing Residents

ABSTRACTBackground:Anxiety and depression are common in older adult public housing residents and frequently co-occur. To understand anxiety and depression more fully in this socioeconomically disadvantaged population, this study relies on the Social Antecedent Model of Psychopathology to characterize anxiety and depression symptoms concurrently.Methods:190 public housing residents aged 60 years and older in Rochester, New York, participated in a research interview during which they reported on variables across the six stages of the Social Antecedent Model. GAD-7 and PHQ-9 assessed anxiety and depression symptoms, respectively.Results:In these older adult residents, anxiety and depression symptom severity scores were correlated (r = 0.61; p < 0.001). Correlates of anxiety and depression symptom severity were similar for both outcomes and spanned the six stages of the Social Antecedent Model. Multivariate linear regression models identified age, medical comorbidity, mobility, social support, maladaptive coping, and recent life events severity as statistically significant correlates. The regression models accounted for 43% of anxiety and 48% of depression symptom variability.Conclusions:In public housing residents, late-life anxiety and depression symptoms were moderately correlated. Anxiety symptom severity correlates were largely consistent with those found for depression symptom severity. The broad distribution of correlates across demographic, social, medical, and behavioral domains suggests that the context of late-life anxiety and depression symptomatology in public housing is complex and that multidisciplinary collaborative care approaches may be warranted in future interventions.

scholarly journals An examination of the bidirectional relationship between functioning and symptom levels in patients with anxiety disorders in the CALM study

2014 ◽  
Vol 45 (3) ◽  
pp. 647-661 ◽  
Author(s):  
L. A. Brown ◽  
J. L. Krull ◽  
P. Roy-Byrne ◽  
C. D. Sherbourne ◽  
M. B. Stein ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Functional Impairment ◽  
Symptom Severity ◽  
Behavioral Therapy ◽  
Anxiety And Depression ◽  
Computer Assisted ◽  
Depression Symptom ◽  
Subsequent Time ◽  
Subsequent Time Point ◽  
Time Point

BackgroundPatients with anxiety disorders suffer marked functional impairment in their activities of daily living. Many studies have documented that improvements in anxiety symptom severity predict functioning improvements. However, no studies have investigated how improvements in functioning simultaneously predict symptom reduction. We hypothesized that symptom levels at a given time point will predict functioning at the subsequent time point, and simultaneously that functioning at a given time point will predict symptom levels at a subsequent time point.MethodPatients were recruited from primary-care centers for the Coordinated Anxiety Learning and Management (CALM) study and were randomized to receive either computer-assisted cognitive-behavioral therapy and/or medication management (ITV) or usual care (UC). A cross-lagged panel design examined the relationship between functional impairment and anxiety and depression symptom severity at baseline, 6-, 12-, and 18-month follow-up assessments.ResultsProspective prediction of functioning from symptoms and symptoms from functioning were both important in modeling these associations. Anxiety and depression predicted functioning as strongly as functioning predicted anxiety and depression. There were some differences in these associations between UC and ITV. Where differences emerged, the UC group was best modeled with prospective paths predicting functioning from symptoms, whereas symptoms and functioning were both important predictors in the ITV group.ConclusionsTreatment outcome is best captured by measures of functional impairment as well as symptom severity. Implications for treatment are discussed, as well as future directions of research.

scholarly journals A Randomized Placebo-Controlled Trial of Low-Dose Testosterone Therapy in Women With Anorexia Nervosa

2019 ◽  
Vol 104 (10) ◽  
pp. 4347-4355 ◽  
Author(s):  
Allison Kimball ◽  
Melanie Schorr ◽  
Erinne Meenaghan ◽  
Katherine N Bachmann ◽  
Kamryn T Eddy ◽  
...  
Keyword(s):  
Anorexia Nervosa ◽  
Placebo Group ◽  
Eating Disorder ◽  
Symptom Severity ◽  
Anxiety Symptom ◽  
Low Dose ◽  
Rating Scale ◽  
Controlled Trial ◽  
Depression Symptom ◽  
Testosterone Therapy

Abstract Context Anorexia nervosa (AN) is a psychiatric illness with considerable morbidity and no approved medical therapies. We have shown that relative androgen deficiency in AN is associated with greater depression and anxiety symptom severity. Objective To determine whether low-dose testosterone therapy is an effective endocrine-targeted therapy for AN. Design Double-blind, randomized, placebo-controlled trial. Setting Clinical research center. Participants Ninety women, 18 to 45 years, with AN and free testosterone levels below the median for healthy women. Intervention Transdermal testosterone, 300 μg daily, or placebo patch for 24 weeks. Main Outcome Measures Primary end point: body mass index (BMI). Secondary end points: depression symptom severity [Hamilton Depression Rating Scale (HAM-D)], anxiety symptom severity [Hamilton Anxiety Rating Scale (HAM-A)], and eating disorder psychopathology and behaviors. Results Mean BMI increased by 0.0 ± 1.0 kg/m2 in the testosterone group and 0.5 ± 1.1 kg/m2 in the placebo group (P = 0.03) over 24 weeks. At 4 weeks, there was a trend toward a greater decrease in HAM-D score (P = 0.09) in the testosterone vs placebo group. At 24 weeks, mean HAM-D and HAM-A scores decreased similarly in both groups [HAM-D: −2.9 ± 4.9 (testosterone) vs −3.0 ± 5.0 (placebo), P = 0.72; HAM-A: −4.5 ± 5.3 (testosterone) vs −4.3 ± 4.4 (placebo), P = 0.25]. There were no significant differences in eating disorder scores between groups. Testosterone therapy was safe and well tolerated with no increase in androgenic side effects compared with placebo. Conclusion Low-dose testosterone therapy for 24 weeks was associated with less weight gain—and did not lead to sustained improvements in depression, anxiety, or disordered eating symptoms—compared with placebo in women with AN.

scholarly journals Eating Disorder Severity and Psychological Morbidity in Adolescents with Anorexia Nervosa or Atypical Anorexia Nervosa and Premorbid Overweight/Obesity

2021 ◽  
Author(s):  
Abigail Matthews ◽  
Rachel A. Kramer ◽  
Laurie Mitan
Keyword(s):  
Anorexia Nervosa ◽  
Eating Disorder ◽  
Symptom Severity ◽  
Multidisciplinary Treatment ◽  
Significant Proportion ◽  
The United States ◽  
Weight Stigma ◽  
Psychological Morbidity ◽  
Anxiety And Depression ◽  
Atypical Anorexia Nervosa

Abstract PurposeA significant proportion of adolescents with anorexia nervosa (AN) or atypical anorexia nervosa (AAN) experience premorbid overweight/obesity, yet distinct characteristics among this subset of patients remain unclear. This study examined eating disorder (ED) symptom severity, psychological morbidity, and weight stigma in patients with premorbid overweight/obesity as compared to patients with premorbid normal weights.MethodsParticipants included adolescents with AN or AAN (aged 12-18) who received multidisciplinary treatment at a pediatric medical center in the United States. ED symptoms, anxiety, and depression were compared among patients with premorbid overweight/obesity (n = 43) and premorbid normal weights (n = 63). Associations between weight stigma, ED severity, and psychological morbidity were also examined. ResultsPatients with premorbid overweight/obesity reported greater ED severity (p = .04), anxiety (p < .003), depression (p = .02), and a higher frequency of weight-based teasing by peers (p = .003) and parent weight talk about their own weights (p < .001). Weight-based teasing was positively associated with ED symptoms, anxiety, and depression for all patients, regardless of premorbid weight status.ConclusionsAdolescents with AN or AAN and a history of overweight/obesity may present with greater ED symptom severity and psychological morbidity than patients with normal weight histories. Distinct prevention and treatment interventions for adolescents with AN or AAN and premorbid overweight/obesity may be warranted. Level of EvidenceLevel III, case-control analytic study

Predicting MDD with a Semistructured Depression Symptom Severity Interview in Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 862-P
Author(s):  
AMIT SHAPIRA ◽  
VANCE ZEMON ◽  
STEVEN SAFREN ◽  
JEFFREY S. GONZALEZ
Keyword(s):  
Type 2 Diabetes ◽  
Symptom Severity ◽  
Depression Symptom

scholarly journals Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble Dépressif Majeur: Une Étude Can-Bind-1

2020 ◽  
pp. 070674372097482
Author(s):  
Shane J. McInerney ◽  
Trisha Chakrabarty ◽  
Malgorzata Maciukiewicz ◽  
Benicio N. Frey ◽  
Glenda M. MacQueen ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cognitive Functioning ◽  
Symptom Severity ◽  
Cognitive Change ◽  
Cognitive Domain ◽  
Depression Symptom ◽  
Major Depressive ◽  
Occupational Functioning ◽  
The Impact

Objectives: Major depressive disorder (MDD) is associated with impairments in both cognition and functioning. However, whether cognitive deficits significantly contribute to impaired psychosocial and occupational functioning, independent of other depressive symptoms, is not well established. We examined the relationship between cognitive performance and functioning in depressed patients before and after antidepressant treatment using secondary data from the first Canadian Biomarker Integration Network in Depression-1 study. Methods: Cognition was assessed at baseline in unmedicated, depressed participants with MDD ( n = 207) using the Central Nervous System Vital Signs computerized battery, psychosocial functioning with the Sheehan Disability Scale (SDS), and occupational functioning with the Lam Employment Absence and Productivity Scale (LEAPS). Cognition ( n = 181), SDS ( n = 175), and LEAPS ( n = 118) were reassessed after participants received 8 weeks of open-label escitalopram monotherapy. A series of linear regressions were conducted to determine (1) whether cognitive functioning was associated with psychosocial and occupational functioning prior to treatment, after adjusting for overall depressive symptom severity and (2) whether changes in cognitive functioning after an 8-week treatment phase were associated with changes in psychosocial and occupational functioning, after adjusting for changes in overall symptom severity. Results: Baseline global cognitive functioning, after adjusting for depression symptom severity and demographic variables, was associated with the SDS work/study subscale (β = −0.17; P = 0.03) and LEAPS productivity subscale (β = −0.17; P = 0.05), but not SDS total (β = 0.19; P = 0.12) or LEAPS total (β = 0.41; P = 0.17) scores. Although LEAPS and SDS scores showed significant improvements after 8 weeks of treatment ( P < 0.001), there were no significant associations between changes in cognitive domain scores and functional improvements. Conclusion: Cognition was associated with occupational functioning at baseline, but changes in cognition were not associated with psychosocial or occupational functional improvements following escitalopram treatment. We recommend the use of more comprehensive functional assessments to determine the impact of cognitive change on functional outcomes in future research.

Sign in / Sign up

Export Citation Format

Share Document